TABLE 2.
Spike IgG antibodies titres and vaccination side effects stratified by sex, BMI, HCW's position and previous exposure to SARS‐CoV‐2
| Sex | BMI | HCW's position | Previous COVID‐19 | |||||
|---|---|---|---|---|---|---|---|---|
| Variable | Female (n = 51) | Male (n = 28) | <30 kg/m2 (n = 58) | ≥30 kg/m2 (n = 21) | Non‐medical (n = 6) | Medical (n = 73) | No (n = 62) | Yes (n = 17) |
| Age (years) | 42 (37–47) | 41 (35–43) | 42 (35–46) | 42 (38–45) | 41 (33–52) | 42 (37–46) | 42 (38–46) | 37 (34–42) |
| Spike IgG titres (UA/ml)—first dose | 89 (61–150) | 76 (47–1010) | 76 (59–150) | 101 (67–153) | 91 (84–99) | 83 (59–153) | 75 (52–107) | 2210 (1040–3310)† |
| Spike IgG titres (UA/ml)—second dose | 338 (282–1345) | 382 (293–1650) | 343 (280–1440) | 367 (317–1375) | 1700 (1350–1970)§ | 348 (284–1280) | 328 (279–386) | 1935 (386–2100)† |
| Side effects—first dose | ||||||||
| Pain | 37 (72.5%) | 21 (75%) | 41 (71%) | 17 (81%) | 2 (33%) | 56 (77%)‡ | 45 (73%) | 13 (76.5%) |
| Headache | 17 (33%) | 6 (21%) | 17 (29%) | 6 (28.5%) | 4 (67%)|| | 19 (26%) | 15 (24%) | 8 (47%)¶ |
| Diarrhoea | 3 (6%) | 1 (3.5%) | 2 (3.5%) | 2 (9.5%) | 0 (0%) | 4 (5.5%) | 4 (6.5%) | 0 (0%) |
| Abdominal pain | 4 (8%) | 1 (3.5%) | 3 (5%) | 2 (9.5%) | 0 (0%) | 5 (7%) | 5 (8%) | 0 (0%) |
| Fever | 3 (6%) | 4 (14%) | 3 (5%) | 4 (19%) ^ | 0 (0%) | 7 (9.5%) | 7 (11%) | 0 (0%) |
| Myalgias/arthralgias | 11 (21.5%) | 5 (18%) | 11 (19%) | 5 (24%) | 2 (33%) | 14 (19%) | 12 (19%) | 4 (23.5%) |
| Fatigue | 20 (39%) | 8 (28.5%) | 21 (36%) | 7 (33%) | 4 (67%) | 24 (33%) | 20 (32%) | 8 (47%) |
| Side effects—second dose | ||||||||
| Pain | 37 (74%) | 21 (75%) | 42 (74%) | 16 (76%) | 5 (83%) | 53 (74%) | 45 (73%) | 13 (76.5%) |
| Headache | 17 (34%) | 7 (25%) | 20 (35%) | 4 (19%) | 5 (83%)∆ | 19 (26%) | 18 (29.5%) | 6 (35%) |
| Diarrhoea | 3 (6%) | 0 (0%) | 3 (5%) | 0 (0%) | 2 (33%)∫ | 1 (1.5%) | 3 (5%) | 0 (0%) |
| Abdominal pain | 4 (8%) | 0 (0%) | 4 (7%) | 0 (0%) | 2 (33%)∞ | 2 (3%) | 4 (6.5%) | 0 (0%) |
| Fever | 7 (14%) | 1 (3.5%) | 5 (9%) | 3 (14%) | 2 (33%) | 6 (8%) | 6 (10%) | 2 (11.5%) |
| Myalgias/arthralgias | 13 (26%) | 7 (25%) | 16 (28%) | 4 (19%) | 3 (50%) | 17 (24%) | 16 (26%) | 4 (23.5%) |
| Fatigue | 25 (51%)* | 8 (28.5%) | 25 (44%) | 8 (40%) | 6 (100%)Ω | 27 (38%) | 26 (43.5%) | 7 (41%) |
Note: Between‐group comparisons were performed as follows: Wilcoxon's rank sum test for continuous variables and Fisher's exact test for categorical variables. Sex: *p = 0.062. BMI: ^ p = 0.076. HCW's position: § p = 0.064; ‡ p = 0.04; || p = 0.056; ∆ p = 0.009; ∫ p = 0.014; ∞ p = 0.029; Ω p = 0.005. Previous COVID‐19: † p < 0.001; ¶ p = 0.078.
Abbreviations: BMI, body mass index; COVID‐19, coronavirus disease 2019; HCW, healthcare worker; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; UA, arbitrary units.